Shares of biotech firm Virpax Pharmaceuticals (VRPX.O) fall 55.2% to 54 cents VRPX’s stock to be delisted from Nasdaq tomorrow for failing to meet minimum stockholders’ equity requirement - SEC filing
Co does not plan to appeal the delisting decision
Three board members and CFO, Usama Chaudhry, have resigned from their positions, effective immediately
Including session’s move, stock down 94% YTD

VRPX

Shares of biotech firm Virpax Pharmaceuticalsfall 55.2% to 54 cents VRPX’s stock to be delisted from Nasdaq tomorrow for failing to meet minimum stockholders’ equity requirement - SEC filingCo does not plan to appeal the delisting decisionThree board members and CFO, Usama Chaudhry, have resigned from their positions, effective immediatelyIncluding session’s move, stock down 94% YTD

- Virpax Pharmaceuticals' shares fell 55.2% to 54 cents, leading to its delisting from Nasdaq due to insufficient stockholders' equity.  
- The company will not appeal the delisting decision, and three board members, including CFO Usama Chaudhry, have resigned immediately.  
- Year-to-date, the stock has declined by 94%.  

BUZZ-Virpax Pharma plunges as Nasdaq delisting looms